Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2016

Filing Date
Filed February 17, 2017
Period End
December 31, 2016
Security
IDXX
One revenue dollarkept$0.13
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 10-K filed February 17, 2017. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' 2016 10-K shows a company that grew revenue 10.8% to $1.775 billiona (11.4% organic growth), with operating income up 16.8% to $350.2 million and diluted EPS of $2.44, up from $2.05.

Growth was led by the Companion Animal Group (CAG), where recurring diagnostic revenue (about 72% of consolidated revenue) rose 11.7%, driven by IDEXX VetLab consumables, reference laboratory services, and the new SediVue Dx urinalysis analyzer. Management also highlights the 2015-2016 benefits of the U.S. all-direct sales transition, which is now behind the company, although competitive pressure from former distributors and up-front customer loyalty incentives remain headwinds. Balance sheet and cash flow were strong in operating terms: operating cash flow rose to $334.6 millionb from $216.4 million, and cash plus marketable securities reached $391.8 million.

Stockholders' equity is negative ($108.2 millionc deficit) because of $1.63 billion in cumulative treasury stock from heavy buybacks ($317 million in 2016). Leverage is moderate on a covenant basis, with gross debt of $1.21 billion (2.66x adjusted EBITDA) and net debt of $816 million (1.80x). Working capital is negative ($89.0 million), largely because the $611 million revolving credit facility is classified as current due to a subjective material adverse event clause.

Investors should also note the 39% international revenue exposure and the stronger U.S. dollar drag (about $26 milliond revenue impact projected for 2017), plus the pending Mars-VCA merger that could shift reference laboratory testing volumes. The company does not pay dividends and has no current plans to do so.

Capital returns are instead made through share repurchases, with 3.7 million shares remaining under the 65 million share authorization at year-end. The 2017 outlook includes capital expenditures of about $90 million and an expected $0.12 to $0.16 EPS benefit from the ASU 2016-09 adoption, which will flow through the income statement starting in Q1 2017.

Key Highlights

  1. Revenue grew 10.8% to $1,775.4 million (11.4% organic), with CAG contributing $1,522.7 million, up 12.3%.
  2. Recurring CAG Diagnostics revenue reached $1,281.3 million (about 72% of consolidated revenue), led by IDEXX VetLab consumables (+13.9%) and reference laboratory services (+13.5%).
  3. Operating income rose 16.8% to $350.2 million (19.7% margin); diluted EPS increased 19% to $2.44 from $2.05.
  4. Operating cash flow more than doubled... rising 54.6% to $334.6 million, while capex was $64.8 million.
  5. Stockholders' equity is a deficit of $(108.2) million, reflecting $1.63 billion of cumulative treasury stock repurchases; the company repurchased $313.1 million of stock in 2016 and pays no dividends.
  6. Leverage is covenant-compliant: gross debt to adjusted EBITDA of 2.66x and net debt to adjusted EBITDA of 1.80x against a 3.5x maximum; $238 million of Credit Facility capacity remained at year-end.
  7. Key risks include 39% international revenue exposure, a stronger U.S. dollar (projected $26 million revenue headwind in 2017), competitive pressure from former U.S. distributors, and consolidation among corporate veterinary hospitals (Mars-VCA deal expected to close Q3 2017).

Follow one dollar

Of each $1.00 of revenue in FY2016, IDEXX Laboratories kept $0.13.

  1. Revenue$1.78B100.0%
  2. Cost of revenue−$800.0M45.1%
  3. Gross profit$975.4M54.9%
  4. Operating costs−$625.2M35.2%
  5. Operating income$350.2M19.7%
  6. Interest, other & tax−$128.2M7.2%
  7. Net income$222.0M12.5%
Computed from 10-KFY2016filed February 17, 2017Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2016 revenue went

$1.78B
  • Cost of revenue: $800.0M, 45% of revenue
  • Other operating costs: $524.1M, 30% of revenue
  • Net income: $222.0M, 13% of revenue
  • R&D: $101.1M, 5.7% of revenue
  • Interest, other & tax: $128.2M, 7.2% of revenue

Kept 13% as net income

Full revenue history →

Financial Statements

FY2016 against FY2015

Line itemFY2016FY2015Change
Revenue$1.78B$1.60B+10.8%
Cost of Revenue$799.99M$711.62M+12.4%
Gross Profit$975.44M$890.27M+9.6%
R&D Expenses$101.12M$99.68M+1.4%
Operating Income$350.24M$299.91M+16.8%
Interest Expense$32.05M$29.24M+9.6%
Net Income$222.04M$192.08M+15.6%
EPS (Basic)$2.47$2.07+19.3%
EPS (Diluted)$2.44$2.05+19.0%
Shares Outstanding (Basic)89.73M92.60M−3.1%
Shares Outstanding (Diluted)90.88M93.65M−3.0%

Frequently Asked Questions

  1. What drove IDEXX's revenue growth in 2016?

    Growth was driven primarily by CAG Diagnostics recurring revenue, which rose 11.7% to $1,281.3 million. IDEXX VetLab consumables grew 13.9% on higher Catalyst analyzer volumes, and reference laboratory revenue grew 13.5% on higher testing volumes and price increases. Newly launched SediVue Dx added about 23 percentage points to CAG instrument revenue growth.

  2. Why is IDEXX's stockholders' equity negative?

    Stockholders' equity is a deficit of $(108.2) million at December 31, 2016, because cumulative treasury stock repurchases of $1,633.4 million exceed retained earnings of $540.4 million plus paid-in capital. The company has repurchased shares aggressively over many years and does not pay dividends, so a negative book equity position is a function of capital allocation rather than operating losses.

  3. Does IDEXX have liquidity concerns given negative working capital?

    Working capital was negative $89.0 million, but this mainly reflects the $611.0 million Credit Facility being classified as current because of a subjective material adverse event clause, even though the facility matures in December 2020. Management states that cash and marketable securities of $391.8 million, operating cash flow of $334.6 million, and $238 million of remaining borrowing availability are sufficient to fund operations for at least the next twelve months.

  4. What are the main risks to IDEXX's 2017 outlook?

    Management highlights a strengthening U.S. dollar, which would reduce 2017 revenue by about $26 million and operating profit by about $8 million at current exchange rates. Other risks include increasing competition from former U.S. distributors now selling competing products, potential reference lab vertical integration if Mars acquires VCA, and reduced government-funded testing in livestock and water markets. The company also faces a $0.12 to $0.16 EPS tailwind from share-based compensation accounting changes.

  5. Will IDEXX pay dividends or continue buybacks?

    IDEXX has never paid a cash dividend and has no current intention to do so. Its primary return of capital is share repurchases, which totaled $313.1 million in 2016 (3.1 million shares). The Board has authorized up to 65 million shares in total, with 3,735,508 shares remaining available at year-end 2016.